{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:03:38Z","timestamp":1781273018541,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004300","name":"Senior Talent Foundation of Jiangsu University","doi-asserted-by":"publisher","award":["5501290017"],"award-info":[{"award-number":["5501290017"]}],"id":[{"id":"10.13039\/501100004300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejmech.2026.118853","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:21:50Z","timestamp":1775895710000},"page":"118853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and evaluation of furo[3,2-c]pyridine-based MNK1\/2 inhibitors for the treatment of colorectal cancer"],"prefix":"10.1016","volume":"311","author":[{"given":"Xinrui","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8600-7737","authenticated-orcid":false,"given":"Huibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118853_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-024-01749-9","article-title":"Protein translation: biological processes and therapeutic strategies for human diseases","volume":"9","author":"Jia","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118853_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc.2017.30","article-title":"New frontiers in translational control of the cancer genome","volume":"17","author":"Truitt","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118853_bib3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1261\/rna.080340.124","article-title":"eIF4F-mediated dysregulation of mRNA translation in cancer","volume":"31","author":"Amiri","year":"2025","journal-title":"Rna"},{"key":"10.1016\/j.ejmech.2026.118853_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102368","article-title":"Human eukaryotic initiation factor 4E (eIF4E) and the nucleotide-bound state of eIF4A regulate eIF4F binding to RNA","volume":"298","author":"Izidoro","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1039\/D3MD00121K","article-title":"Medicinal chemistry approaches to target the MNK-eIF4E axis in cancer","volume":"14","author":"Fernandez","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109689","article-title":"Phosphorylation of the mRNA cap-binding protein eIF4E and cancer","volume":"73","author":"Yang","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2026.118853_bib7","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1021\/acs.jmedchem.4c03158","article-title":"Discovery of potent and selective MNK kinase inhibitors for the treatment of leukemia","volume":"68","author":"Vagadia","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117911","article-title":"Discovery of novel hydrazinyl thiazole derivatives as potent anticancer agents by inhibiting eIF4E\/eIF4G interactions","volume":"297","author":"Yao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib9","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60151","article-title":"eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis","volume":"9","author":"Ruan","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.118853_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116499","article-title":"Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2-d]pyrimidine derivatives as Mnk1\/2 inhibitors","volume":"272","author":"Xing","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113420","article-title":"Progress in developing MNK inhibitors","volume":"219","author":"Jin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib12","doi-asserted-by":"crossref","first-page":"15617","DOI":"10.1021\/acs.jmedchem.5c00504","article-title":"Discovery of a novel MNK inhibitor (NSP-1047) with in vivo anti-acute myeloid leukemia activity","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib13","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1021\/acs.jmedchem.3c02441","article-title":"Discovery of D25, a potent and selective MNK inhibitor for sepsis-associated acute spleen injury","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib14","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.4161\/cbt.8.15.8960","article-title":"Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues","volume":"8","author":"Fan","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2026.118853_bib15","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1158\/0008-5472.CAN-04-2677","article-title":"Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities","volume":"64","author":"Topisirovic","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118853_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2025.12.050","article-title":"Discovery of a small-molecule inhibitor of eIF4E suppressing tumor proliferation via lipid metabolic reprogramming","author":"Lin","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ejmech.2026.118853_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110687","article-title":"Dephosphorylation of astrocyte elevated gene-1 protein upregulates eIF4E expression to promote gastric cancer progression","volume":"301","author":"Zhao","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1158\/1535-7163.MCT-22-0092","article-title":"Inhibition of the MNK1\/2-eIF4E axis augments palbociclib-mediated antitumor activity in melanoma and breast cancer","volume":"22","author":"Prabhu","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118853_bib19","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118853_bib20","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1158\/2159-8290.CD-20-0652","article-title":"MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression","volume":"11","author":"Knight","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118853_bib21","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.bbrc.2018.06.150","article-title":"Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer","volume":"503","author":"Xi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.118853_bib22","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1021\/acs.jmedchem.7b01795","article-title":"Structure-based design of pyridone-aminal eFT508 targeting dysregulated translation by selective mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1\/2) inhibition","volume":"61","author":"Reich","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-596","article-title":"eFT508, a potent and highly selective inhibitor of MNK1\/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity","volume":"77","author":"Webster","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118853_bib24","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-596","article-title":"Abstract PR11: eFT508: an oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade","volume":"77","author":"Webster","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118853_bib25","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acs.jmedchem.1c00368","article-title":"Update on the development of MNK inhibitors as therapeutic agents","volume":"65","author":"Xu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-018-0321-2","article-title":"Translation control of the immune checkpoint in cancer and its therapeutic targeting","volume":"25","author":"Xu","year":"2019","journal-title":"Nature medicine"},{"key":"10.1016\/j.ejmech.2026.118853_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1158\/1078-0432.CCR-24-0841","article-title":"Phase Ib pharmacodynamic study of the MNK inhibitor tomivosertib (eFT508) combined with paclitaxel in patients with refractory metastatic breast cancer","volume":"31","author":"Ferrario","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118853_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e14145","article-title":"A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed\/refractory microsatellite stable colorectal cancer (MSS CRC)","volume":"37","author":"Hubbard","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2025","key":"10.1016\/j.ejmech.2026.118853_bib29","article-title":"Dual MNK\/VEGFR2 inhibitor JDB153 enhances immunotherapeutic efficiency and chemosensitivity in lung cancer","volume":"6","author":"Xu","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2026.118853_bib30","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1021\/acs.jmedchem.7b01714","article-title":"Optimization of selective mitogen-activated protein kinase interacting kinases 1 and 2 inhibitors for the treatment of blast crisis leukemia","volume":"61","author":"Yang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib31","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1021\/acs.jmedchem.3c02008","article-title":"Development of an imidazopyridazine-based MNK1\/2 inhibitor for the treatment of lymphoma","volume":"67","author":"Yuan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116186","article-title":"Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1\/2 inhibitors","volume":"40","author":"Bu","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/biom15101406","article-title":"NEK family kinases: structure, function, and role in disease","volume":"15","author":"Baker","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2026.118853_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213898","article-title":"MET signaling pathways, resistance mechanisms, and opportunities for target therapies","volume":"23","author":"Rivas","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118853_bib35","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118853_bib36","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:46:40Z","timestamp":1781272000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"alternative-id":["S0223523426002989"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118853","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and evaluation of furo[3,2-c]pyridine-based MNK1\/2 inhibitors for the treatment of colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118853"}}